All Stories

  1. BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

    Article • Blood Cancer Discovery, June 2026, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  2. A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 Trial

    Article • Cancers, May 2026, MDPI AG

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  3. Exploring Resistance to ETS Targeting Agents in Diffuse Large B‐Cell Lymphoma

    Article • Cancer Medicine, May 2026, Wiley

    Dr Francesco Bertoni

  4. CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors

    Article • February 2026, openRxiv

    Dr Francesco Bertoni

  5. The biology of marginal zone lymphoma subtypes: challenge and relevance of classification

    Article • Blood, January 2026, American Society of Hematology

    Dr Francesco Bertoni

  6. Characterization of lymphoma models for the surface ROR1 expression

    Article • November 2025, openRxiv

    Dr Francesco Bertoni

  7. A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK)

    Article • ESMO Open, November 2025, Elsevier

    Dr Francesco Bertoni

  8. Polatuzumab vedotin and CD79B : A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma

    Article • British Journal of Haematology, October 2025, Wiley

    Dr Francesco Bertoni

  9. Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma

    Article • September 2025, openRxiv

    Dr Francesco Bertoni

  10. Comprehensive analysis of 177 Lu ‐lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunothera...

    Article • British Journal of Haematology, September 2025, Wiley

    Dr Francesco Bertoni

  11. Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies

    Article • September 2025, openRxiv

    Dr Francesco Bertoni

  12. Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma

    Article • ChemBioChem, September 2025, Wiley

    Dr Francesco Bertoni

  13. Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient

    Article • Cell Death and Disease, July 2025, Springer Science + Business Media

    Dr Francesco Bertoni

  14. KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas

    Article • Cancers, June 2025, MDPI AG

    Dr Francesco Bertoni

  15. Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma Models

    Article • eJHaem, June 2025, Wiley

    Dr Francesco Bertoni

  16. Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300

    Article • ChemMedChem, April 2025, Wiley

    Dr Francesco Bertoni

  17. The Genetic Landscape of Canine Tumors: Insights from the Canine Cancer Genome Atlas (CCGA)

    Article • September 2024, Springer Science + Business Media

    Dr Francesco Bertoni

  18. Comprehensive Analysis of 177 Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

    Article • June 2024, openRxiv

    Dr Francesco Bertoni

  19. The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification

    Article • February 2024, Springer Science + Business Media

    Dr Francesco Bertoni

  20. EasyCircR: Detection and reconstruction of circular RNAs post-transcriptional regulatory interaction networks

    Article • December 2023, openRxiv

    Dr Francesco Bertoni

  21. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B‐cell lymphoma?

    Article • Hematological Oncology, November 2023, Wiley

    Dr Francesco Bertoni

  22. Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  23. Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  24. Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  25. Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  26. Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  27. Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  28. Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  29. Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  30. Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  31. Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  32. Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  33. Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • April 2023, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  34. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

    Article • Journal of Clinical Medicine, January 2023, MDPI AG

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  35. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

    Article • Exploration of Targeted Anti-tumor Therapy, December 2022, Open Exploration Publishing

    Dr Francesco Bertoni

  36. HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols

    Article • Gigabyte, December 2022, GigaScience Press

    Dr Francesco Bertoni

  37. Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades

    Article • Cancers, April 2022, MDPI AG

    Dr Francesco Bertoni

  38. Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity

    Article • European Journal of Medicinal Chemistry Reports, July 2021, Elsevier

    Dr Francesco Bertoni

  39. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

    Article • Blood Advances, May 2021, American Society of Hematology

    Dr Francesco Bertoni

  40. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma

    Article • Oncogene, May 2021, Springer Science + Business Media

    Dr Francesco Bertoni

  41. Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation

    Article • Non-Coding RNA, April 2021, MDPI AG

    Dr Francesco Bertoni

  42. Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma

    Article • Frontiers in Veterinary Science, March 2021, Frontiers

    Dr Francesco Bertoni

  43. The Essentials of Marine Biotechnology

    Article • Frontiers in Marine Science, March 2021, Frontiers

    Professor Lada Lukić Bilela, Dr Francesco Bertoni

  44. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

    Article • Drug Resistance Updates, March 2021, Elsevier

    Dr Francesco Bertoni

  45. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer

    Article • Nature Communications, February 2021, Springer Science + Business Media

    Dr Francesco Bertoni

  46. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

    Article • Marine Drugs, December 2020, MDPI AG

    Professor Lada Lukić Bilela, Dr Francesco Bertoni

  47. DNA Copy Number Changes in Diffuse Large B Cell Lymphomas

    Article • Frontiers in Oncology, December 2020, Frontiers

    Dr Francesco Bertoni

  48. Targeting BET bromodomain proteins in cancer: The example of lymphomas

    Article • Pharmacology & Therapeutics, November 2020, Elsevier

    Dr Francesco Bertoni

  49. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences

    Article • Cancer Treatment Reviews, November 2020, Elsevier

    Dr Francesco Bertoni

  50. Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types

    Article • Journal of Medicinal Chemistry, September 2020, American Chemical Society (ACS)

    Dr Francesco Bertoni

  51. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

    Article • Blood Advances, September 2020, American Society of Hematology

    Dr Francesco Bertoni

  52. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond

    Article • Annals of Lymphoma, September 2020, AME Publishing Company

    Dr Francesco Bertoni

  53. Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type

    Article • Cancers, July 2020, MDPI AG

    Dr Francesco Bertoni

  54. An overview on anti-tubulin agents for the treatment of lymphoma patients

    Article • Pharmacology & Therapeutics, July 2020, Elsevier

    Dr Francesco Bertoni

  55. Marginal Zone Lymphomas

    Article • The Cancer Journal, July 2020, Wolters Kluwer Health

    Dr Francesco Bertoni

  56. A New Network for the Advancement of Marine Biotechnology in Europe and Beyond

    Article • Frontiers in Marine Science, May 2020, Frontiers

    Dr Francesco Bertoni

  57. HMGA1-pseudogene7 transgenic mice develop B cell lymphomas

    Article • Scientific Reports, April 2020, Springer Science + Business Media

    Dr Francesco Bertoni

  58. Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog

    Article • Veterinary and Comparative Oncology, March 2020, Wiley

    Dr Francesco Bertoni

  59. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

    Article • Blood Advances, March 2020, American Society of Hematology

    Dr Francesco Bertoni

  60. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

    Article • International Journal of Molecular Sciences, February 2020, MDPI AG

    Dr Francesco Bertoni

  61. Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

    Article • Modern Pathology, February 2020, Elsevier

    Dr Francesco Bertoni

  62. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

    Article • Modern Pathology, February 2020, Elsevier

    Dr Francesco Bertoni

  63. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

    Article • Haematologica, January 2020, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  64. Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors

    Article • RSC Medicinal Chemistry, January 2020, Royal Society of Chemistry

    Dr Francesco Bertoni

  65. STAT6 activation correlates with cerebrospinal fluid IL‐4 and IL‐10 and poor prognosis in primary central nervous system lymphoma

    Article • Hematological Oncology, November 2019, Wiley

    Dr Francesco Bertoni

  66. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

    Article • Frontiers in Oncology, November 2019, Frontiers

    Dr Francesco Bertoni

  67. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines

    Article • European Journal of Medicinal Chemistry, November 2019, Elsevier

    Dr Francesco Bertoni

  68. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

    Article • Haematologica, September 2019, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  69. Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization

    Article • Non-Coding RNA, September 2019, MDPI AG

    Dr Francesco Bertoni

  70. Primary central nervous system lymphoma: Novel precision therapies

    Article • Critical Reviews in Oncology/Hematology, September 2019, Elsevier

    Dr Francesco Bertoni

  71. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents

    Article • Clinical Cancer Research, August 2019, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  72. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

    Article • Haematologica, August 2019, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  73. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas

    Article • British Journal of Haematology, July 2019, Wiley

    Dr Francesco Bertoni

  74. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

    Article • Molecular Cancer Therapeutics, July 2019, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  75. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies

    Article • Current Opinion in Hematology, July 2019, Wolters Kluwer Health

    Dr Francesco Bertoni

  76. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

    Article • Leukemia & Lymphoma, June 2019, Taylor & Francis

    Dr Francesco Bertoni

  77. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

    Article • Cancers, June 2019, MDPI AG

    Dr Francesco Bertoni

  78. Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq

    Article • PLOS One, April 2019, PLOS

    Dr Francesco Bertoni

  79. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses

    Article • Haematologica, April 2019, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  80. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

    Article • Blood, April 2019, American Society of Hematology

    Dr Francesco Bertoni

  81. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma

    Article • Leukemia, March 2019, Springer Science + Business Media

    Dr Francesco Bertoni

  82. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    Article • PLOS One, February 2019, PLOS

    Margarita Sanchez-Beato, Dr Francesco Bertoni

  83. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

    Article • Haematologica, February 2019, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  84. Genome-wide promoter methylation of hairy cell leukemia

    Article • Blood Advances, February 2019, American Society of Hematology

    Dr Francesco Bertoni

  85. Targeted Therapy in Translational Cancer ResearchApostolia‐MariaTsimberidouRazelleKurzrockKenneth C.Anderson. Wiley‐Blackwell, 2016, 400pp., Ebook (130 euros) or Hardcover (144 euros)

    Article • Hematological Oncology, February 2019, Wiley

    Dr Francesco Bertoni

  86. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

    Article • Haematologica, January 2019, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  87. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

    Article • Blood, January 2019, American Society of Hematology

    Dr Francesco Bertoni

  88. A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study

    Article • January 2019, Springer Science + Business Media

    Dr Francesco Bertoni

  89. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas

    Article • British Journal of Haematology, December 2018, Wiley

    Dr Francesco Bertoni

  90. New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease

    Article • Haematologica, December 2018, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  91. Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach

    Article • PLOS One, December 2018, PLOS

    Dr Francesco Bertoni

  92. Correction to: cuRnet: an R package for graph traversing on GPU

    Article • BMC Bioinformatics, November 2018, Springer Science + Business Media

    Dr Francesco Bertoni

  93. The involvement of microRNA in the pathogenesis of Richter syndrome

    Article • Haematologica, November 2018, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  94. cuRnet: an R package for graph traversing on GPU

    Article • BMC Bioinformatics, October 2018, Springer Science + Business Media

    Dr Francesco Bertoni

  95. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals

    Article • Hematological Oncology, August 2018, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  96. T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways

    Article • Frontiers in Oncology, August 2018, Frontiers

    Dr Francesco Bertoni

  97. Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

    Article • Nature Genetics, August 2018, Springer Science + Business Media

    Dr Francesco Bertoni

  98. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

    Article • Haematologica, August 2018, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  99. Pixantrone: novel mode of action and clinical readouts

    Article • Expert Review of Hematology, June 2018, Taylor & Francis

    Dr Francesco Bertoni

  100. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

    Article • Blood, May 2018, American Society of Hematology

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  101. Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma

    Article • British Journal of Haematology, April 2018, Wiley

    Dr Francesco Bertoni, Luciano Cascione, RAFFAELLA GATTA

  102. Recent advances in understanding the biology of marginal zone lymphoma

    Article • F1000Research, March 2018, Faculty of 1000, Ltd.

    Emanuele Zucca, Dr Francesco Bertoni, Prof. Emanuele Zucca

  103. A prize-collecting Steiner tree application for signature selection to stratify diffuse large B-cell lymphoma subtypes

    Article • February 2018, openRxiv

    Dr Francesco Bertoni

  104. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias

    Article • Haematologica, February 2018, Ferrata Storti Foundation (Haematologica)

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  105. Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides

    Article • Journal of Biological Chemistry, February 2018, American Society for Biochemistry & Molecular Biology (ASBMB)

    Maurizio Molinari, Dr Francesco Bertoni

  106. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines

    Article • Targeted Oncology, February 2018, Springer Science + Business Media

    Dr Francesco Bertoni

  107. IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas

    Article • Cancers, January 2018, MDPI AG

    Dr Francesco Bertoni

  108. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

    Article • Nature Genetics, January 2018, Springer Science + Business Media

    Dr Francesco Bertoni

  109. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

    Article • Clinical Cancer Research, January 2018, American Association for Cancer Research (AACR)

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  110. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

    Article • ESMO Open, January 2018, Elsevier

    Dr Francesco Bertoni

  111. BET Proteins as Targets for Anticancer Treatment

    Article • Cancer Discovery, January 2018, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  112. OmicsNet: Integration of Multi-Omics Data using Path Analysis in Multilayer Networks

    Article • December 2017, openRxiv

    Dr Francesco Bertoni

  113. TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line

    Article • British Journal of Haematology, October 2017, Wiley

    Dr Francesco Bertoni, Dr Francesco Paduano, Dr Francesco Paduano

  114. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors

    Article • Nature Medicine, August 2017, Springer Science + Business Media

    Dr Francesco Bertoni

  115. Let's give BACH2 a breath of fresh air

    Article • Blood, August 2017, American Society of Hematology

    Dr Francesco Bertoni

  116. PCSF: An R-package for network-based interpretation of high-throughput data

    Article • PLoS Computational Biology, July 2017, PLOS

    Dr Francesco Bertoni

  117. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

    Article • British Journal of Haematology, July 2017, Wiley

    Dr Francesco Bertoni, Luciano Cascione

  118. ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration

    Article • Oncotarget, June 2017, Impact Journals, LLC

    Dr Francesco Bertoni

  119. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

    Article • British Journal of Haematology, June 2017, Wiley

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  120. Lecture Notes: Oncology, 3rd Edition. Mark Bower and Jonathan Waxman. Wiley-Blackwell, 2016, Ebook/Paperback, 352 pp., Prices starting from 23.80 euros

    Article • Hematological Oncology, June 2017, Wiley

    Dr Francesco Bertoni

  121. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth

    Article • Blood, April 2017, American Society of Hematology

    Dr Francesco Bertoni

  122. Methylation patterns in marginal zone lymphoma

    Article • Best Practice & Research Clinical Haematology, March 2017, Elsevier

    Dr Francesco Bertoni

  123. Dnmt3a restrains mast cell inflammatory responses

    Article • Proceedings of the National Academy of Sciences, February 2017, Proceedings of the National Academy of Sciences

    Dr Francesco Bertoni

  124. A Fast Prize-Collecting Steiner Forest Algorithm for Functional Analyses in Biological Networks

    Article • January 2017, Springer Science + Business Media

    Dr Francesco Bertoni

  125. Staining the target: CD37 expression in lymphomas

    Article • Blood, December 2016, American Society of Hematology

    Dr Francesco Bertoni

  126. Inhibition of CHK 1 and WEE 1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation

    Article • British Journal of Haematology, December 2016, Wiley

    Dr Francesco Bertoni

  127. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

    Article • Oncotarget, December 2016, Impact Journals, LLC

    Dr Francesco Bertoni

  128. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence

    Article • Nature Communications, December 2016, Springer Science + Business Media

    MD Letizia Gnetti, Dr Francesco Bertoni

  129. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)

    Article • European Journal of Cancer, December 2016, Elsevier

    Dr Francesco Bertoni

  130. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL)

    Article • European Journal of Cancer, December 2016, Elsevier

    Dr Francesco Bertoni

  131. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

    Article • Oncotarget, November 2016, Impact Journals, LLC

    Dr Francesco Bertoni

  132. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes

    Article • Oncotarget, October 2016, Impact Journals, LLC

    Dr Francesco Bertoni

  133. The genetics of nodal marginal zone lymphoma

    Article • Blood, September 2016, American Society of Hematology

    Dr Francesco Bertoni

  134. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma

    Article • Oncotarget, August 2016, Impact Journals, LLC

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  135. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells

    Article • Leukemia, June 2016, Springer Science + Business Media

    Dr Francesco Bertoni

  136. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

    Article • Annals of Oncology, June 2016, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  137. The genetic landscape of dural marginal zone lymphomas

    Article • Oncotarget, May 2016, Impact Journals, LLC

    Dr Francesco Bertoni

  138. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance

    Article • Blood, April 2016, American Society of Hematology

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  139. Bayesian network data imputation with application to survival tree analysis

    Article • Computational Statistics & Data Analysis, January 2016, Elsevier

    Dr Francesco Bertoni

  140. Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines

    Article • January 2016, Springer Science + Business Media

    Dr Francesco Bertoni

  141. Histologic transformation in marginal zone lymphomas

    Article • Annals of Oncology, November 2015, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  142. Life expectancy of young adults with follicular lymphoma

    Article • Annals of Oncology, November 2015, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  143. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

    Article • Blood, October 2015, American Society of Hematology

    Ph. D, MIAC Franco Fulciniti, Dr Francesco Bertoni

  144. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Dr Francesco Bertoni

  145. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

    Article • OncoImmunology, August 2015, Taylor & Francis

    Claudio Tripodo, Dr Francesco Bertoni

  146. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models

    Article • British Journal of Haematology, August 2015, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  147. Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

    Article • Cancer Cell, May 2015, Elsevier

    Dr Francesco Bertoni

  148. Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

    Article • Cancer Cell, April 2015, Elsevier

    Dr Francesco Bertoni

  149. Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer

    Article • Cell Reports, April 2015, Elsevier

    Dr Francesco Bertoni

  150. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

    Article • Clinical Cancer Research, January 2015, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  151. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

    Article • Blood, January 2015, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  152. Genetic lesions in diffuse large B-cell lymphomas

    Article • Annals of Oncology, January 2015, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  153. The transcription factor ETS1 in lymphomas: friend or foe?

    Article • Leukemia & Lymphoma, January 2015, Taylor & Francis

    Dr Francesco Bertoni

  154. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas

    Article • British Journal of Haematology, January 2015, Wiley

    Dr Francesco Bertoni

  155. Two types of BCR interactions are positively selected during leukemia development in the E -TCL1 transgenic mouse model of CLL

    Article • Blood, January 2015, American Society of Hematology

    Dr Francesco Bertoni

  156. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor

    Article • Oncotarget, December 2014, Impact Journals, LLC

    Dr Francesco Bertoni

  157. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

    Article • Leukemia, December 2014, Springer Science + Business Media

    Dr Francesco Bertoni, Ph. D, MIAC Franco Fulciniti

  158. 568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM)

    Article • European Journal of Cancer, November 2014, Elsevier

    Dr Francesco Bertoni

  159. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

    Article • Oncotarget, October 2014, Impact Journals, LLC

    Dr Francesco Bertoni

  160. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas

    Article • Clinical Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  161. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas

    Article • Leukemia & Lymphoma, October 2014, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  162. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma

    Article • Leukemia, October 2014, Springer Science + Business Media

    Dr Francesco Bertoni

  163. Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  164. Abstract CT402: A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL)

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  165. Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  166. Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  167. Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione

  168. Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  169. Abstract 2219: STAT3 network dissection in ALK positive Anaplastic Large Cell Lymphomas

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  170. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

    Article • Clinical Cancer Research, August 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  171. Physiopathogenesis of Hematological Cancer. Estela MariaNovak and Eduardo MagalhãesRego‬. Bentham Science Publishers, Sharjah, 2012, U.A.E. Ebook/Print-on-Demand, 255pp., USD 109/131

    Article • Hematological Oncology, June 2014, Wiley

    Dr Francesco Bertoni

  172. Emerging Cancer Therapeutics: Lymphomas. John Sweetenham(guest editor). Demos Medical Publishing, 2012, New York, NY, USA. Hardcover edition, 389 pp., USD 85.00

    Article • Hematological Oncology, March 2014, Wiley

    Dr Francesco Bertoni

  173. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type

    Article • Seminars in Cancer Biology, February 2014, Elsevier

    Dr Francesco Bertoni

  174. MYCnetwork mutations in high-risk chronic lymphocytic leukaemia

    Article • Hematological Oncology, January 2014, Wiley

    Dr Francesco Bertoni

  175. Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia

    Article • Genes Chromosomes and Cancer, December 2013, Wiley

    Dr Francesco Bertoni

  176. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas

    Article • British Journal of Haematology, December 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  177. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation

    Article • Leukemia, December 2013, Springer Science + Business Media

    Dr Francesco Bertoni, FRANCESC SOLE

  178. Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices

    Article • PLOS One, November 2013, PLOS

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  179. Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL).

    Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  180. Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma.

    Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  181. Abstract A129: Novel histone deacetylase inhibitors ITF-A and ITF-B exhibit efficacy in preclinical models of mature B-cell lymphomas.

    Article • Molecular Cancer Therapeutics, November 2013, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  182. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma

    Article • Blood, September 2013, American Society of Hematology

    Dr Francesco Bertoni

  183. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

    Article • Blood, September 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  184. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

    Article • Blood, September 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  185. Toward New Treatments for Mantle-Cell Lymphoma?

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  186. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma

    Article • Blood, August 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  187. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ fromde novodiffuse large B-cell lymphoma

    Article • British Journal of Haematology, August 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  188. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis

    Article • Current Opinion in Hematology, July 2013, Wolters Kluwer Health

    Dr Francesco Bertoni

  189. The changing paradigm of chronic lymphocytic leukemia management

    Article • European Journal of Internal Medicine, July 2013, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  190. Prognostic impact of monocyte count at presentation in mantle cell lymphoma

    Article • British Journal of Haematology, June 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  191. MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT

    Article • June 2013, Future Medicine

    Dr Francesco Bertoni

  192. Pathologic diagnosis: molecular genetics

    Article • June 2013, Taylor & Francis

    Dr Francesco Bertoni

  193. Genome-wide high resolution DNA profiling of hairy cell leukaemia

    Article • British Journal of Haematology, May 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  194. Abstract 3853: Humanized NOD/Scid/IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  195. Abstract 1017: The BRD-inhibitor OTX015 affects proliferation and gene expression of cells derived from mature lymphoid neoplasms.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  196. Risk factors of central nervous system relapse in mantle cell lymphoma

    Article • Leukemia & Lymphoma, February 2013, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  197. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH

    Article • Annals of Oncology, January 2013, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  198. MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma)

    Article • January 2013, Springer Science + Business Media

    Dr Francesco Bertoni

  199. Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas

    Article • January 2013, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  200. Where Do We Stand in the Genomics of Lymphomas?

    Article • December 2012, Springer Science + Business Media

    Dr Francesco Bertoni

  201. Gains ofCCND3gene in ocular adnexal MALT lymphomas: an integrated analysis

    Article • British Journal of Haematology, December 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  202. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

    Article • Blood, December 2012, American Society of Hematology

    Dr Francesco Bertoni, Josep Nomdedeu

  203. MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, November 2012, Taylor & Francis

    Dr Francesco Bertoni

  204. 528 The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL)

    Article • European Journal of Cancer, November 2012, Elsevier

    Dr Francesco Bertoni

  205. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice

    Article • British Journal of Haematology, October 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  206. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development

    Article • Journal of Experimental Medicine, August 2012, Rockefeller University Press

    Dr Francesco Bertoni

  207. Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial

    Article • Journal of Clinical Oncology, July 2012, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  208. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma

    Article • Blood, June 2012, American Society of Hematology

    Dr Francesco Bertoni

  209. Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells

    Article • Cancer Science, June 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  210. An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

    Article • International Journal of Gynecological Cancer, June 2012, Wolters Kluwer Health

    Dr Francesco Bertoni

  211. MYD88 somatic mutations in MALT lymphomas

    Article • British Journal of Haematology, May 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  212. Abstract 4575: Three-gene diagnostic classifier for ALK negative ALCL

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  213. Incidence, risk factors and outcome of histological transformation in follicular lymphoma

    Article • British Journal of Haematology, February 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  214. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

    Article • Haematologica, February 2012, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  215. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

    Article • Blood, February 2012, American Society of Hematology

    Dr Francesco Bertoni

  216. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia

    Article • Journal of Translational Medicine, January 2012, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  217. ALK signaling and target therapy in anaplastic large cell lymphoma

    Article • Frontiers in Oncology, January 2012, Frontiers

    Ph. D, MIAC Franco Fulciniti, Dr Francesco Bertoni

  218. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes

    Article • Haematologica, December 2011, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  219. Absence of NOTCH1 gene mutations in MALT lymphomas

    Article • British Journal of Haematology, December 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  220. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array

    Article • British Journal of Haematology, November 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  221. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

    Article • Blood, October 2011, American Society of Hematology

    Dr Francesco Bertoni

  222. Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia

    Article • Leukemia Research, October 2011, Elsevier

    Dr Francesco Bertoni

  223. Alteration of BIRC3 and multiple other NF- B pathway genes in splenic marginal zone lymphoma

    Article • Blood, August 2011, American Society of Hematology

    Dr Francesco Bertoni

  224. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma

    Article • Leukemia & Lymphoma, August 2011, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  225. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis

    Article • International Journal of Cancer, August 2011, Wiley

    Dr Francesco Bertoni

  226. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia

    Article • British Journal of Haematology, July 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  227. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion

    Article • Annals of Oncology, June 2011, Oxford University Press (OUP)

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  228. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype

    Article • Hematological Oncology, June 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  229. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

    Article • Journal of Experimental Medicine, June 2011, Rockefeller University Press

    Dr Francesco Bertoni

  230. Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart

    Article • Clinical Oncology and Cancer Research, June 2011, Springer Science + Business Media

    Dr Francesco Bertoni

  231. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines

    Article • Leukemia Research, June 2011, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  232. 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

    Article • Genes Chromosomes and Cancer, May 2011, Wiley

    Dr Francesco Bertoni, Dr ALESSANDRO Gozzetti

  233. Anaplastic lymphoma kinase in human cancer

    Article • April 2011

    Dr Francesco Bertoni

  234. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

    Article • British Journal of Haematology, April 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  235. Genomic profiles of MALT lymphomas: variability across anatomical sites

    Article • Haematologica, April 2011, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  236. Integrated profiling of diffuse large B‐cell lymphoma with 7q gain

    Article • British Journal of Haematology, March 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  237. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas

    Article • Hematological Oncology, March 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  238. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome

    Article • Hematological Oncology, March 2011, Wiley

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  239. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage

    Article • British Journal of Haematology, February 2011, Wiley

    Dr Francesco Bertoni

  240. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas

    Article • British Journal of Haematology, January 2011, Wiley

    Dr Francesco Bertoni

  241. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

    Article • Blood, January 2011, American Society of Hematology

    Dr Francesco Bertoni

  242. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

    Article • Blood, November 2010, American Society of Hematology

    Dr Francesco Bertoni, Claudio Tripodo, Prof. Emanuele Zucca

  243. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma

    Article • British Journal of Haematology, September 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  244. Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas

    Article • Modern Pathology, September 2010, Springer Science + Business Media

    Dr Francesco Bertoni

  245. Syk expression patterns differ among B-cell lymphomas

    Article • Leukemia Research, September 2010, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  246. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21

    Article • British Journal of Haematology, August 2010, Wiley

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  247. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia

    Article • Hematological Oncology, July 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  248. Treatment of gastric marginal zone lymphoma of MALT type

    Article • Expert Opinion on Pharmacotherapy, June 2010, Informa Healthcare

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  249. An integrated Bayesian analysis of LOH and copy number data

    Article • BMC Bioinformatics, June 2010, Springer Science + Business Media

    Dr Francesco Bertoni

  250. Patterns of survival of follicular lymphomas at a single institution through three decades

    Article • Leukemia & Lymphoma, June 2010, Taylor & Francis

    Dr Francesco Bertoni

  251. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma

    Article • Haematologica, May 2010, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  252. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms

    Article • British Journal of Haematology, April 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  253. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells

    Article • International Journal of Cancer, April 2010, Wiley

    Dr Francesco Bertoni, Mariagrazia Uguccioni

  254. The clinical and biological features of a series of immunophenotypic variant of B-CLL

    Article • European Journal Of Haematology, April 2010, Wiley

    Dr Francesco Bertoni

  255. 3 Pathogenesis of ocular adnexal lymphoma

    Article • European Journal of Cancer Supplements, April 2010, Elsevier

    Dr Francesco Bertoni

  256. 57 High-resolution genomic profiling of 533 B-cell lymphomas defines distinct tumor signatures, genomic aberrations correlated with outcome and pathogenetic subgroups

    Article • European Journal of Cancer Supplements, April 2010, Elsevier

    Dr Francesco Bertoni

  257. IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia

    Article • British Journal of Haematology, April 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  258. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort

    Article • Leukemia & Lymphoma, March 2010, Taylor & Francis

    Dr Francesco Bertoni

  259. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma

    Article • British Journal of Haematology, March 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  260. Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features

    Article • Clinical Cancer Research, January 2010, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  261. Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells

    Article • Pathobiology, January 2010, Karger Publishers

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  262. Genome wide DNA-profiling of HIV-related B-cell lymphomas

    Article • British Journal of Haematology, January 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  263. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas

    Article • Hematological Oncology, December 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  264. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03

    Article • Hematological Oncology, September 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  265. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

    Article • Blood, August 2009, American Society of Hematology

    Dr Francesco Bertoni

  266. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect

    Article • Genes Chromosomes and Cancer, July 2009, Wiley

    Dr Francesco Bertoni

  267. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors

    Article • British Journal of Haematology, July 2009, Wiley

    Dr Francesco Bertoni, Dr ALESSANDRO Gozzetti, Valeria Maria Pinto

  268. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

    Article • Clinical Cancer Research, June 2009, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  269. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

    Article • Nature, May 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  270. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome

    Article • Human Pathology, May 2009, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  271. The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

    Article • Blood, March 2009, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  272. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type

    Article • Annals of Oncology, February 2009, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  273. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study

    Article • British Journal of Haematology, February 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  274. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

    Article • Leukemia, January 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  275. Bayesian DNA copy number analysis

    Article • BMC Bioinformatics, January 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  276. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

    Article • Journal of Translational Medicine, January 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  277. Bayesian Joint Estimation of CN and LOH Aberrations

    Article • January 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  278. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance

    Article • Journal of Translational Medicine, January 2009, Springer Science + Business Media

    Dr Francesco Bertoni

  279. Marginal Zone Lymphomas

    Article • Hematology/Oncology Clinics of North America, October 2008, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  280. Up-regulation of the hypoxia-inducible factor–1 transcriptional pathway in colorectal carcinomas

    Article • Human Pathology, October 2008, Elsevier

    Dr Francesco Bertoni

  281. 195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies

    Article • European Journal of Cancer Supplements, October 2008, Elsevier

    Dr Francesco Bertoni

  282. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

    Article • Leukemia Research, October 2008, Elsevier

    Dr Francesco Bertoni

  283. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

    Article • European Journal of Cancer, September 2008, Elsevier

    Dr Francesco Bertoni

  284. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion

    Article • British Journal of Haematology, August 2008, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  285. Pathobiology and molecular basis of MALT lymphoma

    Article • July 2008, Informa Healthcare

    Dr Francesco Bertoni

  286. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia

    Article • British Journal of Haematology, June 2008, Wiley

    Dr Francesco Bertoni

  287. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy

    Article • Annals of Oncology, January 2008, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  288. Hematological Oncology: further ahead

    Article • Hematological Oncology, January 2008, Wiley

    Dr Francesco Bertoni

  289. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells

    Article • European Journal of Immunology, January 2008, Wiley

    Dr Francesco Bertoni

  290. Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers

    Article • Cancer Research, December 2007, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni

  291. Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma

    Article • Genes Chromosomes and Cancer, September 2007, Wiley

    Dr Francesco Bertoni

  292. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas

    Article • British Journal of Haematology, August 2007, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  293. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

    Article • Human Pathology, May 2007, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  294. Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease

    Article • Genes Chromosomes and Cancer, March 2007, Wiley

    Dr Francesco Bertoni

  295. Bendamustine in lymphomas: More to combine?

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  296. ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  297. The cellular origin of mantle cell lymphoma

    Article • The International Journal of Biochemistry & Cell Biology, January 2007, Elsevier

    Dr Francesco Bertoni

  298. Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type

    Article • Hematological Oncology, January 2007, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  299. Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  300. Cyclin-dependent kinase inhibitor seliciclib showsin vitroactivity in diffuse large B-cell lymphomas

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni

  301. A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals

    Article • Pathobiology, January 2007, Karger Publishers

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  302. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma

    Article • Haematologica, January 2007, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni

  303. Chlamydia or Not Chlamydia, That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?

    Article • JNCI Journal of the National Cancer Institute, October 2006, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  304. Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor-δ Activation in Ovarian Cancer Cells

    Article • Neoplasia, October 2006, Elsevier

    Dr Francesco Bertoni

  305. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas

    Article • British Journal of Haematology, July 2006, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  306. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression

    Article • Journal of Experimental Medicine, May 2006, Rockefeller University Press

    Dr Francesco Bertoni

  307. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy

    Article • Nucleic Acids Research, March 2006, Oxford University Press (OUP)

    Dr Francesco Bertoni

  308. Chromosome band 6q deletion pattern in malignant lymphomas

    Article • Cancer Genetics and Cytogenetics, March 2006, Elsevier

    Dr Francesco Bertoni

  309. Update on the molecular biology of mantle cell lymphoma

    Article • Hematological Oncology, January 2006, Wiley

    Dr Francesco Bertoni

  310. Marginal Zone B-Cell Lymphomas

    Article • January 2006, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  311. Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

    Article • January 2006, Elsevier

    Dr Francesco Bertoni

  312. Delving deeper into MALT lymphoma biology

    Article • Journal of Clinical Investigation, December 2005, American Society for Clinical Investigation

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  313. Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets

    Article • The Journal of Immunology, December 2005, The American Association of Immunologists

    Dr Francesco Bertoni

  314. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

    Article • British Journal of Haematology, December 2005, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  315. In Reply:

    Article • Journal of Clinical Oncology, October 2005, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni

  316. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma

    Article • Journal of Clinical Oncology, September 2005, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  317. Another Piece of the MALT Lymphomas Jigsaw

    Article • Journal of Clinical Oncology, August 2005, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  318. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

    Article • Nature Immunology, July 2005, Springer Science + Business Media

    Dr Francesco Bertoni

  319. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas

    Article • Annals of Oncology, July 2005, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  320. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

    Article • Journal of Clinical Oncology, March 2005, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  321. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)

    Article • Journal of Clinical Oncology, February 2005, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni

  322. IgVH mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome

    Article • The Journal of Pathology, January 2005, Wiley

    Dr Francesco Bertoni

  323. Identification of a potential role forPOU2AF1 andBTG4 in the deletion of 11q23 in chronic lymphocytic leukemia

    Article • Genes Chromosomes and Cancer, January 2005, Wiley

    Dr Francesco Bertoni

  324. Mantle cell lymphoma

    Article • Current Opinion in Hematology, November 2004, Wolters Kluwer Health

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  325. 546 A novel aureolic acid antibiotic analogue has potent anti-proliferative activity and induces multiple changes in gene expression in ovarian cancer cells

    Article • European Journal of Cancer Supplements, September 2004, Elsevier

    Dr Francesco Bertoni

  326. 66 Anti-proliferative activity of a PPAR gamma agonist is associated with changes in the expression of cell cycle and apoptosis related genes in human ovarian cancer cells

    Article • European Journal of Cancer Supplements, September 2004, Elsevier

    Dr Francesco Bertoni

  327. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

    Article • British Journal of Haematology, January 2004, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  328. Molecular basis of mantle cell lymphoma

    Article • British Journal of Haematology, December 2003, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  329. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide

    Article • Annals of Oncology, July 2003, Elsevier

    Dr Francesco Bertoni

  330. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia

    Article • Oncogene, January 2003, Springer Science + Business Media

    Dr Francesco Bertoni

  331. Mantle Cell Lymphoma: New Treatments Targeted to the Biology

    Article • Clinical Lymphoma, September 2002, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  332. The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23

    Article • Leukemia, July 2002, Springer Science + Business Media

    Dr Francesco Bertoni

  333. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial

    Article • Blood, April 2002, American Society of Hematology

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  334. Genetic alterations underlying the pathogenesis of MALT lymphoma

    Article • The Hematology Journal, January 2002, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  335. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes

    Article • Blood, August 2001, American Society of Hematology

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  336. Application of genomic real-time PCR to characterise 11q deletions in mantle cell lymphoma and chronic lymphocytic leukaemia

    Article • European Journal of Cancer, April 2001, Elsevier

    Dr Francesco Bertoni

  337. Gastric MALT lymphomas prospective LY03 randomised cooperative trial: preliminary results of the molecular follow-up

    Article • European Journal of Cancer, April 2001, Elsevier

    Dr Francesco Bertoni

  338. Construction of a chromosome 11q22–23 BAC/PAC contig to characterize deletions in lymphoproliferative disorders

    Article • Nature Genetics, April 2001, Springer Science + Business Media

    Dr Francesco Bertoni

  339. MALT lymphoma and other marginal zone lymphomas

    Article • January 2001, Cambridge University Press

    Dr Francesco Bertoni

  340. Dedifferentiated Clear Cell Chondrosarcoma

    Article • The American Journal of Surgical Pathology, August 2000, Wolters Kluwer Health

    Dr Francesco Bertoni

  341. Prognostic models for diffuse large b‐cell lymphoma

    Article • Hematological Oncology, June 2000, Wiley

    Dr Francesco Bertoni

  342. Analysis ofFas/CD95 gene somatic mutations in ovarian cancer cell lines

    Article • International Journal of Cancer, May 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  343. Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines

    Article • International Journal of Cancer, May 2000, Wiley

    Dr Francesco Bertoni

  344. BCL10 gene mutations rarely occur in lymphoid malignancies

    Article • Leukemia, April 2000, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  345. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma

    Article • Digestive and Liver Disease, April 2000, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  346. Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping

    Article • Gastroenterology, April 2000, Elsevier

    Dr Francesco Bertoni

  347. Association of gastric and Waldeyer's ring lymphoma: a molecular study

    Article • Hematological Oncology, March 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  348. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas

    Article • Leukemia, March 2000, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  349. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin

    Article • Human Pathology, February 2000, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  350. Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAlu— Polymerase Chain Reaction

    Article • Leukemia & Lymphoma, January 2000, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  351. Prognostic models for diffuse large b-cell lymphoma

    Article • Hematological Oncology, January 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  352. The effect of Rituximab on patients with follicular and mantle-cell lymphoma

    Article • Annals of Oncology, January 2000, Oxford University Press (OUP)

    Dr Francesco Bertoni

  353. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers

    Article • Genes Chromosomes and Cancer, October 1999, Wiley

    Dr Francesco Bertoni

  354. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers

    Article • Genes Chromosomes and Cancer, October 1999, Wiley

    Dr Francesco Bertoni

  355. Analysis of BCL-10 gene mutations in ovarian cancer cell lines

    Article • Annals of Oncology, October 1999, Elsevier

    Dr Francesco Bertoni

  356. DNA fingerprinting of low-grade extranodal marginal zone B-cell lymphoma (of MALT type)

    Article • European Journal of Cancer, September 1999, Elsevier

    Dr Francesco Bertoni

  357. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers

    Article • European Journal of Cancer, September 1999, Elsevier

    Dr Francesco Bertoni

  358. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites

    Article • Annals of Oncology, September 1999, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  359. Allelic expression of p73 in human ovarian cancers

    Article • Annals of Oncology, August 1999, Elsevier

    Dr Francesco Bertoni

  360. Microsatellite instability in gastric MALT lymphomas and other associated neoplasms

    Article • Annals of Oncology, July 1999, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  361. Molecular Genetics of Extranodal Marginal Zone (MALT-Type) B-Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  362. Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  363. Primary Mediastinal Large B-Cell Lymphoma: The Need for Prospective Controlled Clinical Trials

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  364. Primary Mediastinal Large B-Cell Lymphoma (PMLCL): The Need for Prospective Controlled Clinical Trials

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  365. Clonality Assessment in Blood of Patients with Mantle Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  366. Management of rare forms of lymphoma

    Article • Current Opinion in Oncology, September 1998, Wolters Kluwer Health

    Dr Francesco Bertoni

  367. Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature

    Article • Annals of Hematology, August 1998, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  368. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa

    Article • Annals of Oncology, July 1998, Elsevier

    Dr Francesco Bertoni

  369. Primary extranodal lymphoma of skeletal muscles: a report of four cases.

    Article • Oncology Reports, May 1998, Spandidos Publications

    Dr Francesco Bertoni

  370. Molecular Analysis of the Progression from Helicobacter pylori –Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 1998, New England Journal of Medicine (NEJM/MMS)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  371. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach

    Article • Leukemia, February 1998, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  372. Primary mediastinal diffuse large cell lymphoma (PMLCL): The experience of the servizio di radioterapia and the servizio oncologico cantonale, Ospedale San Giovanni Bellinzona

    Article • International Journal of Radiation Oncology*Biology*Physics, January 1998, Elsevier

    Dr Francesco Bertoni

  373. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas

    Article • Annals of Oncology, August 1997, Elsevier

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  374. Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

    Article • British Journal of Cancer, July 1997, Springer Science + Business Media

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  375. Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process

    Article • British Journal of Haematology, June 1997, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  376. Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma

    Article • Leukemia & Lymphoma, January 1997, Taylor & Francis

    Prof. Emanuele Zucca, Dr Francesco Bertoni

  377. Biological Determinants of Long-Term Survival in Chronic Myelogenous Leukemia Patients Treated with Conventional Chemotherapy

    Article • Acta Haematologica, January 1997, Karger Publishers

    Dr Francesco Bertoni

  378. Palmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?

    Article • Acta Oncologica, January 1997, Acta Dermato-Venereologica

    Dr Francesco Bertoni

  379. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas

    Article • Annals of Oncology, December 1996, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  380. MALT and other marginal zone lymphomas

    Article • Cambridge University Press

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  381. B-cell chronic lymphocytic leukemia

    Article • Cambridge University Press

    Dr Francesco Bertoni